shouldiuse.io

Categories

VERDICT

Should I use Iqvia?

Skip to main content - iqvia.com

Depends. Buy only if you are a large pharma, biotech, or payer that needs healthcare data, real-world evidence, or MLR compliance at global scale. Startups, mid-market teams, and anyone outside life sciences will overpay for capabilities they cannot use.

Confidence

Medium. Based on ~20 public sources; many snippets truncated, so some claims are hedged.

Ratings

  • Value for money
  • Ease of useNo direct product-UX evidence
  • Feature depth
  • Support qualityOnly indirect employee-review evidence
  • Security posture

Pricing

Enterprise (quote-based)

From ~$500 (third-party estimate)

ModelNot disclosed
Monthly feesNot disclosed
HardwareNot disclosed

Best for

  • Large pharma and biotech
  • Medical affairs / MLR compliance teams
  • Market access and pricing analytics
  • Clinical trial sponsors

Not for

  • Startups and small clinics
  • Anyone outside healthcare or life sciences
  • Teams wanting transparent, self-serve pricing
  • Anyone who just needs a simple contact list

Gotchas - check before you buy

high

CNIL fined IQVIA €5M over health data (May 2026) — assess GDPR exposure before signing

medium

Pricing is quote-only; the $500 figure is a third-party estimate, real contracts likely run higher

medium

Mid-market buyers report better coverage-per-dollar from alternatives; IQVIA is not always best value

low

Only 18 G2 product reviews — little independent software UX feedback before purchase

Pros and cons

Pros

  • Sprawling healthcare data, real-world evidence, and compliance portfolio
  • 4.3/5 G2 seller rating
  • Listed among top biopharma business-intelligence services
  • Global operations across many countries

Cons

  • Fined €5M by France's CNIL over health data handling
  • Employee rating just 3.7/5 across 5,700+ reviews
  • No transparent pricing; quote-only enterprise contracts
  • Clinical-research Reddit threads allege poor hiring and management practices

Sources & method

Analyzed 9/29/2026 - 12 sources - No vulnerability reports in reviewed sources, but one €5M French privacy fine over health data (2026) and a 2023 US state breach notice.

official x2review x7security x2news x1
  • CNIL fine over health data, France's CNIL fined IQVIA €5 million (announced May 2026) over health data practices.
  • Massachusetts breach notification, A Feb 2023 Massachusetts breach notice (number 29130) references IQVIA / Advanced Health Media; details unclear from available snippet.

Key stats

  • Value for money: 2/5

    Rating

  • From ~$500 (third-party estimate)

    Starting price

  • 12

    Sources

  • Analyzed

  • Value for money: 2/5. Opaque pricing; mid-market alternatives undercut it
  • Ease of use. No direct product-UX evidence
  • Feature depth: 5/5. Sprawling data, RWE, and compliance portfolio
  • Support quality. Only indirect employee-review evidence
  • Security posture: 2/5. €5M CNIL health-data fine
  • 4.3/5 G2 seller rating 18 product reviews
  • 3.7/5 Employee rating 5,700+ AmbitionBox reviews
  • ~$500 Starting price Third-party estimate; quote-based
  • 15,519 Glassdoor reviews Employee reviews

Pricing

Enterprise (quote-based)

From ~$500 (third-party estimate)

  • Custom data and analytics engagements
  • No public tier list; sales-led pricing

Security

No vulnerability reports in reviewed sources, but one €5M French privacy fine over health data (2026) and a 2023 US state breach notice.

  • CNIL fine over health dataFrance's CNIL fined IQVIA €5 million (announced May 2026) over health data practices.⁴
  • Massachusetts breach notificationA Feb 2023 Massachusetts breach notice (number 29130) references IQVIA / Advanced Health Media; details unclear from available snippet.

What users say

Employee reviews skew mixed (3.7/5 across 5,700+ AmbitionBox reviews), while G2 product feedback is sparse but positive (4.3/5).

Companies that use it

  • Eli Lilly
Full analysis

Based on ~20 public sources; many snippets truncated, so some claims are hedged.

Enterprise healthcare data + CRO powerhouse. Right for big pharma; overkill with quote-only pricing for everyone else.

Methodology

Based on ~20 public sources; many snippets truncated, so some claims are hedged.

Sources

  1. IQVIA Products | Read 18 Reviews on G2g2.com
    review
  2. IQVIA Reviews by 5700+ Employees | Rated 3.7/5ambitionbox.com
    review
  3. IQVIA Reviews (15519) on Glassdoorglassdoor.com
    review
  4. Health data: fine of 5 million euros against IQVIA (CNIL)cnil.fr
    security
  5. IQVIA Holdings Security Rating, Vendor Risk Report (UpGuard)upguard.com
    security
  6. IQVIA Product Security Pageiqvia.com
    official
  7. IQVIA Real World Evidence Solutionsiqvia.com
    official
  8. IQVIA Plans & Hidden Fees (itqlick)itqlick.com
    review
  9. 7 IQVIA Alternatives in 2026: Coverage, Price & Fitglnkco.com
    review
  10. Provyx vs. IQVIA OneKey: Provider Data Comparedgetprovyx.com
    review
  11. NOT GOOD HIRING PRACTICE: IQVIA (Reddit)reddit.com
    review
  12. What are the top Biopharmaceutical Business Intelligence servicesdrugpatentwatch.com
    news

Rate this review

Anonymous. You can change your vote.

Loading votes…

Comments

One queue. No nested comments. Give a display name first. Limit: 200 words per comment and 7 comments per day. You can edit or delete yours.

Save a name to write a comment.

0 / 200 words

No comments yet.